Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BN.1.2.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BN.1.2.8NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XAHORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XAHORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XAHNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XAHNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XAHNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.5.2.5ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BA.5.2.5ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.5.2.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.2.5NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBJ.3ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XBJ.3ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XBJ.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBJ.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBJ.3NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
EP.2ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
EP.2ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
EP.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EP.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EP.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.4.1.5ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BA.4.1.5ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.4.1.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4.1.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.4.1.5NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.4ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BA.2.4ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.2.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.4NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
CL.1.2ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
CL.1.2ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
CL.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CL.1.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CL.1.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBF.8.1ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XBF.8.1ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XBF.8.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBF.8.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBF.8.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XAUORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XAUORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XAUNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XAUNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XAUNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XAY.1.1.2ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XAY.1.1.2ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XAY.1.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used